The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia von Toscan, Cara E., McCalmont, Hannah, Ashoorzadeh, Amir, Lin, Xiaojing, Fu, Zhe, Doculara, Louise, Kosasih, Hansen J., Cadiz, Roxanne, Zhou, Anthony, Williams, Sarah, Evans, Kathryn, Khalili, Faezeh, Cai, Ruilin, Yeats, Kristy L., Gifford, Andrew J., Pickford, Russell, Mayoh, Chelsea, Xie, Jinhan, Henderson, Michelle J., Trahair, Toby N., Patterson, Adam V., Smaill, Jeff B., de Bock, Charles E., Lock, Richard B.

Volltext